PRG-2505

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NamePRG-2505

Drug Alias NamePRG2505PRG-2505V001

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesPregene (Shenzhen) Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical Sciences

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A